Clasado Biosciences has revealed a brand-new distribution agreement with food ingredient and chemical speciality distributor, Deimos Srl.
The deal sees Deimos Srl granted exclusive rights to distribute multi award-winning galactooligosaccharide, Bimuno GOS, to formulators throughout Italy and the Republic of San Marino. Clasado will be working specifically with the Aethra business unit within Deimos Group, which specialises in supplying ingredients to the nutraceutical industry.
Dr Frederic Narbel, VP of B2B Sales at Clasado, said: “We are delighted to announce our new partnership with Deimos Group and the Aethra business unit, further strengthening the European presence and accessibility of Bimuno GOS. Our multi award-winning ingredient is the most comprehensively studied of its kind, making it an excellent fit for Aethra as a prebiotic specialist. Consumers look for products they can trust and Bimuno GOS clearly stands out from the crowd, supported by over 100 scientific publications, including more than 20 clinical trials.”
The Aethra product range includes ingredients and additives that target a number of key health areas. In addition to digestive health, these include joint and bone health, sports nutrition, immune health and mental health and clinical nutrition.
Francesca Mercandelli, Business Manager at Aethra, added: “As the health and nutrition market expands, more and more brands are exploring prebiotic fibre in their new and existing product developments. As the gold standard for galactooligosaccharides, Bimuno GOS makes it easier than ever to create the next generation of consumer-led health and nutrition products.
“We look forward to sharing the strong scientific backing of the ingredient with our customers across Italy. The wealth of research behind it shows impactful results in areas such as gastrointestinal and digestive health, immune health and cognition, and it’s versatile and easy to formulate with. With a wide array of benefits and surging interest in prebiotic fibre ingredients, Bimuno GOS fits perfectly into our strong portfolio of ‘biotics’.”
